Attovia Therapeutics, Inc. (NASDAQ:ATTO) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO) have received an average rating of “Moderate Buy” from the seven analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $42.20.

ATTO has been the subject of a number of research analyst reports. Lifesci Capital began coverage on shares of Attovia Therapeutics in a research report on Monday, August 31st. They set an “outperform” rating and a $45.00 price objective for the company. Citigroup assumed coverage on shares of Attovia Therapeutics in a research note on Monday, August 31st. They set a “buy” rating and a $30.00 target price for the company. Weiss Ratings began coverage on shares of Attovia Therapeutics in a report on Monday. They set a “sell (e-)” rating for the company. Zacks Research upgraded shares of Attovia Therapeutics to a “hold” rating in a research note on Friday, September 4th. Finally, Wall Street Zen raised shares of Attovia Therapeutics to a “sell” rating in a report on Saturday, September 19th.

Attovia Therapeutics Trading Up 2.2%

Shares of Attovia Therapeutics stock opened at $15.60 on Thursday. The company has a market cap of $712.16 million and a PE ratio of -3.20. The business’s 50 day moving average is $18.37. Attovia Therapeutics has a 12-month low of $12.94 and a 12-month high of $28.00.

Attovia Therapeutics (NASDAQ:ATTO) last issued its earnings results on Wednesday, September 2nd. The company reported ($4.88) earnings per share (EPS) for the quarter. The company had revenue of $0.45 million for the quarter. Analysts forecast that Attovia Therapeutics will post -4.06 earnings per share for the current fiscal year.

About Attovia Therapeutics

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company focused on developing antibody-based medicines for immune-mediated and inflammatory diseases. The company is working to address conditions in which existing treatments may not provide adequate efficacy, durability, or convenience.

Attovia uses its proprietary antibody-engineering and drug-development capabilities to discover and advance biologic therapies designed to modulate disease-driving immune pathways.